Free Trial
NYSE:OGEN

Oragenics (OGEN) Stock Price, News & Analysis

Oragenics logo
$1.44 -0.02 (-1.37%)
As of 09:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Oragenics Stock (NYSE:OGEN)

Key Stats

Today's Range
$1.45
$1.47
50-Day Range
$1.42
$6.06
52-Week Range
$1.35
$75.60
Volume
20,191 shs
Average Volume
196,291 shs
Market Capitalization
$1.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oragenics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
1st Percentile Overall Score

OGEN MarketRank™: 

Oragenics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Oragenics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oragenics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oragenics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oragenics has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    42.98% of the float of Oragenics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oragenics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oragenics has recently increased by 258.74%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oragenics does not currently pay a dividend.

  • Dividend Growth

    Oragenics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    42.98% of the float of Oragenics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oragenics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oragenics has recently increased by 258.74%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    4 people have searched for OGEN on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Oragenics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oragenics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.90% of the stock of Oragenics is held by insiders.

  • Percentage Held by Institutions

    Only 18.71% of the stock of Oragenics is held by institutions.

  • Read more about Oragenics' insider trading history.
Receive OGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter.

OGEN Stock News Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
See More Headlines

OGEN Stock Analysis - Frequently Asked Questions

Oragenics' stock was trading at $11.0790 at the beginning of 2025. Since then, OGEN stock has decreased by 86.8% and is now trading at $1.46.

Oragenics, Inc. (NYSE:OGEN) issued its quarterly earnings results on Monday, August, 16th. The company reported ($54.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($72.00) by $18.00.

Shares of Oragenics reverse split on Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), iBio (IBIO), Jaguar Animal Health (JAGX), NIO (NIO), Bionano Genomics (BNGO) and Vaxart (VXRT).

Company Calendar

Last Earnings
8/16/2021
Today
7/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:OGEN
Previous Symbol
NYSE:OGEN
CIK
1174940
Employees
5
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($33.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.66 million
Net Margins
N/A
Pretax Margin
-243,950.00%
Return on Equity
-2,087.95%
Return on Assets
-486.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.93
Quick Ratio
1.93

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
2.39

Miscellaneous

Outstanding Shares
823,000
Free Float
10,979,000
Market Cap
$1.20 million
Optionable
N/A
Beta
0.95
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:OGEN) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners